MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Phenotypic spectrum and longitudinal outcome of Parkinson’s disease patients with psychosis

M.S. Nanjunda Swamy, M.M. Abbas, S.T. Govindappa, P. Basu, R. Ramanathan, U.B. Muthane (Bangalore, India)

Meeting: 2016 International Congress

Abstract Number: 1486

Keywords: Dementia, Levodopa(L-dopa), Parkinsonism, Psychosis

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Psychiatric manifestations

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: We studied the phenotypic characteristics of psychosis in PD patients, their associated risk factors and assessed their long term outcome.

Background: Psychosis in PD is common and an important contributor of disease morbidity and mortality. PD psychosis studies are mostly cross sectional and have focused on visual hallucinations. There are no longitudinal studies from India addressing the phenotypic spectrum and long term outcome of PD psychosis.

Methods: The study involved 50 PD patients with and 50 without psychosis. At baseline following parameters were analysed: age, age at onset, duration of PD, UPDRS motor score, MMSE, Hamilton depression rating score (HDRS), University of Miami PD Hallucinations Questionnaire (UM-PDHQ), Brief Psychiatric Rating Scale (BPRS), gait freezing, sleep and visual abnormalities and medication history. The phenotypic spectrum of psychosis was described. The prevalence of psychosis, dementia and death in these two groups were noted at the end of five years and the baseline factors predicting these outcomes were analysed.

Results: PD psychosis patients were older (68.1±6.8vs 60.04±11.5 years), had increased disease duration (10.2±4.7 vs 6.7±4.3years), severe disease (UPDRS-46.06 +14.91vs 35.22 +15.92), low MMSE (25.36±5.04 vs 27.78±2.96), high HDRS (14.68±7.19 vs 9.9±5.95) and BPRS (42.1±12.01 vs32.22±11.98) scores, more sleep disturbances (50% vs 34%), gait freezing (18% vs6%) and visual abnormalities (12% vs4%). Levodopa daily (747.1±496 vs 507.1±314.9) and levodopa equivalent doses (934.6±538.22 vs 677.84±381.83) were also higher in PD psychosis group. The phenomenology comprised of visual (84%), minor (49%), auditory (55%), tactile (24%), olfactory (16%) hallucinations and delusions (32%). Autoscopic (n: 2) and gustatory (n: 1) hallucinations were also noted. At the end of five years, psychosis persisted in 46%and resolved in 38%, dementia (38% vs 4%) and mortality (38%vs 14%) were high in PD psychosis group compared to controls. New onset psychosis was seen in 10% of PD controls.

Conclusions: Old age, increased disease duration, severe disease, dementia, depression and levodopa intake were the risk factors for psychosis in the present study. A wide range of psychotic symptoms were encountered in addition to the formed visual hallucinations. The mortality in PD psychosis was high. Interestingly the prevalence of psychosis was low in control PD patients.

To cite this abstract in AMA style:

M.S. Nanjunda Swamy, M.M. Abbas, S.T. Govindappa, P. Basu, R. Ramanathan, U.B. Muthane. Phenotypic spectrum and longitudinal outcome of Parkinson’s disease patients with psychosis [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/phenotypic-spectrum-and-longitudinal-outcome-of-parkinsons-disease-patients-with-psychosis/. Accessed October 2, 2026.
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/phenotypic-spectrum-and-longitudinal-outcome-of-parkinsons-disease-patients-with-psychosis/

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley